Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors

被引:6
|
作者
Thangaiah, Judith Jebastin [1 ]
Westling, Brooke E. [1 ]
Roden, Anja C. [1 ]
Giannini, Caterina [1 ]
Tetzlaff, Michael [2 ]
Cho, Woo Cheal [3 ]
Folpe, Andrew L. [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
Epigenetic; H3K27me2; H3K27me3; Immunohistochemistry; Malignant peripheral nerve sheath tumor; Diffuse midline glioma; H3K27-altered; Cutaneous melanoma; Uveal melanoma; UVEAL MELANOMA; MUTATIONS; TRIMETHYLATION; GNAQ; PRC2;
D O I
10.1016/j.anndiagpath.2022.151967
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction: Loss-of-function mutations in EED and SUZ12, core components of the polycomb repressive complex 2 (PRC2), occur in >90% of sporadic and radiation-associated malignant peripheral nerve sheath tumors (MPNST) and in roughly 70% of NF1-related tumors. PRC2 inactivation results in loss of H3K27me3 expression and aberrant downstream transcription. H3K27me3 expression is lost in 40-90% of spindle cell MPNST but is not specific. A single study has suggested that dimethylated H3K27 (H3K27me2) is a more specific marker of MPNST. Methods: We compared the expression of H3K27me3 and H3K27me2 by immunohistochemistry in a series of MPNST (n = 26), neurofibroma (n = 11), conventional dermatofibrosarcoma protuberans (n = 8), fibrosarcomatous dermatofibrosarcoma protuberans (n = 7), spindle cell rhabdomyosarcoma (n = 6), high-risk solitary fibrous tumor (n = 9), dedifferentiated chondrosarcoma (n = 7), synovial sarcoma (n = 9), diffuse midline glioma, H3K27-altered (n = 13), conventional diffuse astrocytoma (n = 2), conventional cutaneous melanoma (n = 8), uveal melanoma (n = 8), cellular blue nevus (n = 17) and melanoma arising in blue nevus (n = 6). Results: H3K27me3 and H3K27me2 expression patterns were concordant in 115/137 (84%) with 85 cases (62%) expressing both markers and 30 cases (22%) showing loss of both. Discordant results were seen in 22 cases (H3K27me3 loss with retained H3K27me2, 10 cases (7%); H3K27me3 expression with H3K27me2 loss, 12 cases (9%)). H3K27me2 loss was not specific for MPNST and was also seen in certain other tumors, in particular those in the "blue nevus family". Conclusion: We conclude that H3K27me2 loss is not specific for MPNST, and like H3K27me3, should be used in the appropriate clinicopathologic, immunohistochemical and molecular genetic context. Loss of H3K27me2 with retained H3K27me3 is a common feature of "blue nevus family" melanocytic tumors known to harbor GNAQ/GNA11 mutations.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] An Immunohistochemical Comparison of H3K27me2 and H3K27me3 Expression with Emphasis on Malignant Peripheral Nerve Sheath Tumors (MPNST), Diffuse Midline Glioma and Melanoma
    McCann, Brooke
    Roden, Anja
    Giannini, Caterina
    Folpe, Andrew
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 827 - 827
  • [2] An Immunohistochemical Comparison of H3K27me2 and H3K27me3 Expression with Emphasis on Malignant Peripheral Nerve Sheath Tumors (MPNST), Diffuse Midline Glioma and Melanoma
    McCann, Brooke
    Roden, Anja
    Giannini, Caterina
    Folpe, Andrew
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 827 - 827
  • [3] Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors
    Otsuka, Hiroshi
    Kohashi, Kenichi
    Yoshimoto, Masato
    Ishihara, Shin
    Toda, Yu
    Yamada, Yuichi
    Yamamoto, Hidetaka
    Nakashima, Yasuharu
    Oda, Yoshinao
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (03) : 417 - 425
  • [4] Intracranial Malignant Peripheral Nerve Sheath Tumor with Loss of H3K27me3 Expression
    Sharain, Rosalind
    Torres-Mora, Jorge
    Raghunathan, Aditya
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (06): : 508 - 508
  • [5] Specificity of H3K27Me3 Loss in Malignant Peripheral Nerve Sheath Tumors
    Pekmezci, Melike
    Cuevas-Ocampo, Areli K.
    Perry, Arie
    Horvai, Andrew E.
    LABORATORY INVESTIGATION, 2017, 97 : 21A - 21A
  • [6] Specificity of H3K27Me3 Loss in Malignant Peripheral Nerve Sheath Tumors
    Pekmezci, Melike
    Cuevas-Ocampo, Areli K.
    Perry, Arie
    Horvai, Andrew E.
    MODERN PATHOLOGY, 2017, 30 : 21A - 21A
  • [7] Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss
    Marchione, Dylan M.
    Lisby, Amanda
    Viaene, Angela N.
    Santi, Mariarita
    Nasrallah, MacLean
    Wang, Li-Ping
    Williams, Erik A.
    Larque, Ana B.
    Chebib, Ivan
    Garcia, Benjamin A.
    Wojcik, John B.
    MODERN PATHOLOGY, 2019, 32 (10) : 1434 - 1446
  • [8] Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors
    Pekmezci, Melike
    Cuevas-Ocampo, Areli K.
    Perry, Arie
    Horvai, Andrew E.
    MODERN PATHOLOGY, 2017, 30 (12) : 1710 - 1719
  • [9] Loss of H3K27 Trimethylation Distinguishes Malignant Peripheral Nerve Sheath Tumors from Histologic Mimics
    Schaefer, Inga-Marie
    Fletcher, Christopher
    Hornick, Jason L.
    MODERN PATHOLOGY, 2016, 29 : 25A - 25A
  • [10] Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics
    Schaefer, Inga-Marie
    Fletcher, Christopher D. M.
    Hornick, Jason L.
    MODERN PATHOLOGY, 2016, 29 (01) : 4 - 13